The award is a three-year contract through the Joint Warfighter Medical Research Program. CodaVax-DENV is Codagenix’s dengue vaccine candidate, according to the Aug. 17 Codagenix news release.
“We are proud to have been selected by the Department of Defense for this award. The funding allows us to advance CodaVax-DENV towards the clinic and assess its potential as a safe and effective option for protecting our troops and high-risk populations across the globe,” J. Robert Coleman, PhD, co-founder and CEO of Codagenix, said. “With our differentiated codon deoptimization approach to vaccine design, we are well positioned to address the traditional hurdles of dengue vaccine development, and we look forward to helping to make widespread protection against this pervasive disease a reality.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
